Open access
Open access
Powered by Google Translator Translator

Archives

IDSA Guidelines on Infection Prevention for Healthcare Personnel Caring for Patients with Suspected or Known COVID-19.

11 Nov, 2021 | 09:01h | UTC

Infectious Diseases Society of America Guidelines on Infection Prevention for Healthcare Personnel Caring for Patients with Suspected or Known COVID-19

 

Commentary on Twitter

 

White-Coat Hypertension: Pathophysiological and Clinical Aspects.

12 Nov, 2021 | 09:48h | UTC

White-Coat Hypertension: Pathophysiological and Clinical Aspects: Excellence Award for Hypertension Research 2020 – Hypertension (free for a limited period)

 

Podcast | COVID Updates: The Outpatient Edition.

11 Nov, 2021 | 08:57h | UTC

COVID Updates: The Outpatient Edition – The Curbsiders

 

Commentary on Twitter

 

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

11 Nov, 2021 | 08:59h | UTC

COVID antiviral pills: what scientists still want to know – Nature

Related:

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

 

M-A: Low vitamin D levels do not aggravate COVID-19 risk or death, and vitamin D supplementation does not improve outcomes in hospitalized patients with COVID-19.

11 Nov, 2021 | 08:53h | UTC

Low vitamin D levels do not aggravate COVID-19 risk or death, and vitamin D supplementation does not improve outcomes in hospitalized patients with COVID-19: a meta-analysis and GRADE assessment of cohort studies and RCTs – Nutritional Journal

 

Perspective | COVID’s endgame: Scientists have a clue about where SARS-CoV-2 is headed.

11 Nov, 2021 | 08:55h | UTC

COVID’s endgame: Scientists have a clue about where SARS-CoV-2 is headed – NPR

 

An Update on Multisystem Inflammatory Syndrome in Children Related to SARS-CoV-2.

11 Nov, 2021 | 08:52h | UTC

An Update on Multisystem Inflammatory Syndrome in Children Related to SARS-CoV-2 – The Pediatric Infectious Diseases Journal

Related:

Ten Things to Know About Multisystem Inflammatory Syndrome in Children (MIS-C).

Cohort study: long term follow-up showed most patients with post–COVID-19 Multisystem Inflammatory Syndrome in Children had good outcomes with no significant medium- or long-term sequelae.

Kawasaki Disease and Multisystem Inflammatory Syndrome in Children: An Overview and Comparison.

Cohort study: Six month follow-up of Multisystem Inflammatory Syndrome in Children.

Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, there was no evidence that recovery differed after primary treatment with intravenous immune globulin (IVIG) alone, IVIG plus glucocorticoids, or glucocorticoids alone.

Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, initial treatment with intravenous immune globulin (IVIG) plus glucocorticoids was associated with a lower risk of new or persistent cardiovascular dysfunction than IVIG alone.

Cohort study showed that the incidence of Multisystem Inflammatory Syndrome in Children (MIS-C) was 316 persons per 1 000 000 SARS-CoV-2 infections in persons younger than 21 years. The incidence was higher among Black, Hispanic or Latino, and Asian or Pacific Islander persons.

Cohort study showed good recovery for most children 6 months after Pediatric Inflammatory Multisystem Syndrome (PIMS-TS) associated with SARS-CoV-2.

Epidemiology of Multisystem Inflammatory Syndrome in Children: A Step Closer to Understanding Who, Where, and When

Neurologic involvement in children and adolescents with COVID-19 or Multisystem Inflammatory Syndrome

Clinical Update: Acute covid-19 and multisystem inflammatory syndrome in children

Differences in characteristics and outcomes of children and adolescents with Multisystem Inflammatory Syndrome in Children (MIS-C) vs. severe acute COVID-19

Cutaneous findings in SARS-CoV-2-associated Multisystem Inflammatory Disease in Children (MIS-C)

SR: Multisystem inflammatory syndrome in children related to COVID-19

Observational study: The combination of Immunoglobulins + Methylprednisolone was associated with a better course of fever compared to Immunoglobulins alone in Multisystem Inflammatory Syndrome in children

ACR Guidance for pediatric patients with multisystem inflammatory syndrome in children associated with SARS‐CoV‐2

New systematic review of Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 infection summarizes the clinical features, management, and outcomes of the disease, showing favorable outcomes for the majority of children

 

Consensus Statement: Advancing the global public health agenda for non-alcoholic fatty liver disease.

11 Nov, 2021 | 08:48h | UTC

Advancing the global public health agenda for NAFLD: a consensus statement – Nature Reviews Gastroenterology & Hepatology

Related:

Clinical Care Pathway for the Risk Stratification and Management of Patients with Nonalcoholic Fatty Liver Disease.

Non-alcoholic fatty liver disease: A patient guideline.

State of the art review: Management of non-alcoholic fatty liver disease

M-A: Non-alcoholic fatty liver disease linked to increased risk of fatal and non-fatal cardiovascular events.

M-A: non-invasive tests for advanced fibrosis can reduce the need for biopsy in patients with non-alcoholic fatty liver disease.

Review: Dietary carbohydrates and fats in nonalcoholic fatty liver disease.

 

Commentary on Twitter

 

RCT: In patients with acute stroke eligible for intravenous alteplase and endovascular treatment, intravenous alteplase before endovascular treatment did not improve outcomes compared to endovascular treatment alone.

11 Nov, 2021 | 08:43h | UTC

A Randomized Trial of Intravenous Alteplase before Endovascular Treatment for Stroke – New England Journal of Medicine (link to abstract – $ for full-text)

 

RCT: In patients with acute myocardial infarction complicated by a reduced left ventricular ejection fraction, pulmonary congestion, or both, Sacubitril–valsartan was not associated with improved outcomes compared to Ramipril.

11 Nov, 2021 | 08:44h | UTC

Angiotensin Receptor–Neprilysin Inhibition in Acute Myocardial Infarction – New England Journal of Medicine (link to abstract – $ for full-text)

 

Whole genome sequencing may improve the diagnosis of rare diseases and shorten diagnostic journeys for patients.

11 Nov, 2021 | 08:46h | UTC

News Release: Whole genome sequencing improves diagnosis of rare diseases and shortens diagnostic journeys for patients – Queen Mary University of London

Original Study: 100,000 Genomes Pilot on Rare-Disease Diagnosis in Health Care — Preliminary Report – New England Journal of Medicine

Related:

RCT: Effect of whole-genome sequencing on the clinical management of acutely ill infants with suspected genetic disease.

Review: Genome sequencing as a diagnostic test.

 

RCT: Universal screening in high schools can help identify and initiate treatment for depression in adolescents.

11 Nov, 2021 | 08:35h | UTC

Screening in High Schools to Identify, Evaluate, and Lower Depression Among Adolescents: A Randomized Clinical Trial – JAMA Network Open

News release: School-based screening increases identification of, treatment for depression – Penn State

Commentaries:

Universal Depression Screening in Schools—Promises and Challenges in Addressing Adolescent Mental Health Need – JAMA Network Open

Universal School-Based Depression Screening May Connect More Students to Care – Psychiatric News Alert

 

Commentaries on Twitter

 

M-A: Offspring’s risk for suicidal behavior in relation to parental death by suicide – “the experience of losing a parent to suicide is a strong and independent risk factor for suicidal behavior in offspring”.

11 Nov, 2021 | 08:39h | UTC

Offspring’s risk for suicidal behaviour in relation to parental death by suicide: systematic review and meta-analysis and a model for familial transmission of suicide – The British Journal of Psychiatry

 

Commentary on Twitter

 

RCT: Effects of ketamine vs. midazolam on neurocognition at 24 hours in depressed patients with suicidal ideation.

11 Nov, 2021 | 08:37h | UTC

Effects of Ketamine Versus Midazolam on Neurocognition at 24 Hours in Depressed Patients With Suicidal Ideation – The Journal of Clinical Psychiatry (link to abstract – $ for full-text)

Commentary: Ketamine Rapidly Improves Cognitive Function Making Those in Suicidal Crisis Less Likely to Harm Themselves – Columbia University Irving Medical Center

 

A New Dementia Test Raises More Questions Than Answers – “A 5-minute assessment on an iPad could transform how we screen for dementia—or overwhelm the health care system with worried test-takers”.

11 Nov, 2021 | 08:29h | UTC

A New Dementia Test Raises More Questions Than Answers – Wired

 

Clinical Review on the Management of Hormone Receptor–Positive Metastatic Breast Cancer.

11 Nov, 2021 | 08:32h | UTC

Clinical Review on the Management of Hormone Receptor–Positive Metastatic Breast Cancer – JCO Oncology Practice

 

Systematic Review: Beta‐blockers in patients without heart failure after myocardial infarction.

11 Nov, 2021 | 08:25h | UTC

Summary: Benefits and harms of beta-blockers versus placebo or no intervention in the non-acute phase of a myocardial infarction – Cochrane Library

Original Study: Beta‐blockers in patients without heart failure after myocardial infarction – Cochrane Library

 

Systematic Review: Agents for ovarian stimulation for intrauterine insemination (IUI) in ovulatory women with infertility.

11 Nov, 2021 | 08:23h | UTC

Summary: Which medicines are most effective for women trying to get pregnant by ‘intrauterine insemination’ (where sperm is placed directly in the womb)? – Cochrane Library

Original Study: Agents for ovarian stimulation for intrauterine insemination (IUI) in ovulatory women with infertility – Cochrane Library

 

Systematic Review: Prevention of dementia and decline in cognition by using multi-domain interventions.

11 Nov, 2021 | 08:27h | UTC

Summary: Prevention of dementia and decline in cognition by using multi-domain interventions – Cochrane Library

Original Study: Multi‐domain interventions for the prevention of dementia and cognitive decline – Cochrane Library

 

RCT: Pfizer vaccine shows 90.7% efficacy for preventing Covid-19 in children 5 to 11 years of age.

10 Nov, 2021 | 07:24h | UTC

Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age – New England Journal of Medicine

 

Commentary on Twitter

 

How an outbreak became a pandemic: a chronological analysis of crucial junctures and international obligations in the early months of the COVID-19 pandemic.

10 Nov, 2021 | 07:22h | UTC

How an outbreak became a pandemic: a chronological analysis of crucial junctures and international obligations in the early months of the COVID-19 pandemic – The Lancet

 

Commentary on Twitter

 

[Preprint] RCT: In hypoxic but not critically ill patients with COVID-19, an intervention to increase prone positioning did not improve outcomes.

10 Nov, 2021 | 07:20h | UTC

RCT: Prone positioning of patients with moderate hypoxia due to COVID-19 – medRxiv

Related:

RCT: Awake prone positioning reduces the need for intubation in patients with COVID-19.

RCT: Awake prone positioning in patients with hypoxemic respiratory failure due to COVID-19 – no difference in intubation rates compared to standard care.

M-A: Prone positioning of nonintubated patients with Covid-19 improve oxygenation variables without any reported serious adverse events – randomized trials with patient-relevant outcomes such as the need for intubation or mortality rates are required

 

Commentary from the author on Twitter (thread – click for more)

 

French health authority advises against Moderna Covid-19 vaccine for under 30s.

10 Nov, 2021 | 07:18h | UTC

French Health Authority Advises Against Moderna COVID-19 Vaccine for Under 30s – Reuters

See also: France advises against Moderna for under-30s over rare heart risk – Associated Press

Related: Sweden, Denmark pause Moderna COVID-19 vaccine for younger age groups.

 

Commentary on Twitter

 

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

10 Nov, 2021 | 07:13h | UTC

A prominent virologist warns COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm – Science

Original viewpoint: Supercharging New Viral Variants: The Dangers Of Molnupiravir (Part 1) – Forbes

Related:

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

 

Opinion | Protective immunity after recovery from SARS-CoV-2 infection.

10 Nov, 2021 | 07:15h | UTC

Protective immunity after recovery from SARS-CoV-2 infection – The Lancet Infectious Diseases

 

Commentary on Twitter

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.